Dapagliflozin in Patients with CKD and Diabetes
Direct Answer
Initiate dapagliflozin 10 mg once daily in patients with diabetes and CKD if eGFR ≥25 mL/min/1.73 m² for cardiovascular and renal protection, regardless of glycemic control needs or baseline HbA1c. 1, 2
Patient Eligibility and Pre-Initiation Assessment
Check eGFR before starting:
- eGFR ≥45 mL/min/1.73 m²: Initiate for both glycemic control and cardiorenal protection 2
- eGFR 25-44 mL/min/1.73 m²: Initiate for cardiorenal protection only (glucose-lowering efficacy is minimal but cardiovascular/renal benefits are preserved) 1, 2
- eGFR <25 mL/min/1.73 m²: Do not initiate, but if already on treatment, continue 10 mg daily until dialysis 2
Assess volume status before initiation:
- Correct volume depletion before starting dapagliflozin 1, 2
- Consider reducing concurrent diuretic doses in patients at high risk for volume depletion 1
High-priority features for initiation:
- Albuminuria with UACR ≥200 mg/g 1
- Established cardiovascular disease or heart failure 3
- Multiple cardiovascular risk factors 2
Dosing Algorithm
Standard dose for all indications: 10 mg orally once daily 1, 2
For glycemic control specifically (if eGFR ≥45 mL/min/1.73 m²):
- Start 5 mg once daily
- May increase to 10 mg once daily if additional glycemic control needed 2
Critical point: The 10 mg dose is fixed for cardiovascular and renal protection—no titration required or recommended 1, 4
Medication Adjustments at Initiation
If patient is on insulin or sulfonylurea:
- Reduce doses of these medications to prevent hypoglycemia 1
- Monitor glucose closely in the first 2-4 weeks 1
If patient is on diuretics:
- Consider dose reduction to prevent excessive volume depletion 1
- Reassess volume status within 1-2 weeks 4
Continue ACE inhibitors/ARBs without adjustment 1
Expected eGFR Changes and Monitoring
Anticipate an acute eGFR dip:
- Expect a reversible decline of 2-5 mL/min/1.73 m² within the first 2-4 weeks 4, 5
- This acute dip is hemodynamic, not harmful, and predicts better long-term renal outcomes 4, 5
- Do not discontinue dapagliflozin solely because of this initial eGFR decline 1, 4
Monitoring schedule:
- Check eGFR within 1-2 weeks after initiation 4
- If eGFR decreases >30% from baseline AND signs of hypovolemia present, reduce diuretic doses first 4
- Continue monitoring eGFR every 3-6 months if eGFR 25-59 mL/min/1.73 m² 4
Long-term eGFR trajectory:
- After the initial dip, dapagliflozin slows eGFR decline by approximately 1-2 mL/min/1.73 m²/year compared to placebo 5
- Greater benefit in patients with higher baseline albuminuria and HbA1c 5
Evidence-Based Benefits
Renal protection:
- 44% reduction in kidney-specific composite outcome (sustained eGFR decline ≥50%, ESKD, or renal death) 3, 6
- 39% reduction in primary composite outcome (sustained eGFR decline, ESKD, or cardiovascular/renal death) 3, 6
Cardiovascular protection:
- 29% reduction in cardiovascular death or heart failure hospitalization 3, 6
- 31% reduction in all-cause mortality 4
Benefits are consistent regardless of:
- Presence or absence of type 2 diabetes 7, 8
- Baseline glycemic status (normoglycemia, prediabetes, or diabetes) 7
- Etiology of CKD (diabetic nephropathy, glomerulonephritis, hypertensive/ischemic CKD) 8
Safety Precautions and Patient Education
Withhold dapagliflozin during:
- Acute illness with reduced oral intake, fever, vomiting, or diarrhea 1, 4
- At least 3 days before major surgery or procedures requiring prolonged fasting 1, 2
Educate patients about:
- Genital mycotic infections (occur in ~6% vs 1% placebo)—maintain daily hygiene 1, 4
- Euglycemic diabetic ketoacidosis risk—seek medical attention if malaise, nausea, vomiting, or abdominal pain develops even with normal glucose 1, 4
- Increased urination is expected and not a reason to stop 6
Maintain at least low-dose insulin in insulin-requiring patients even when dapagliflozin is temporarily held 1, 4
Common Pitfalls to Avoid
Do not discontinue dapagliflozin when:
- eGFR falls below 45 mL/min/1.73 m² (cardiovascular and renal benefits persist) 1, 4
- Initial eGFR dip occurs in first 2-4 weeks (this is expected and beneficial) 4, 5
- Glucose-lowering efficacy diminishes at lower eGFR (continue for cardiorenal protection) 1, 4
Do not reduce the dose below 10 mg for cardiovascular/renal indications 1, 2
Do not delay initiation waiting for "optimal" glycemic control—benefits are independent of baseline HbA1c 4
Integration with Other CKD Therapies
Dapagliflozin is first-line therapy alongside:
- ACE inhibitors or ARBs (continue without adjustment) 1
- Mineralocorticoid receptor antagonists like finerenone (benefits appear additive; dapagliflozin may reduce hyperkalemia risk) 1
SGLT2 inhibitors are positioned as foundational therapy for CKD progression and cardiovascular event prevention, regardless of glycemia 1